Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Slides:



Advertisements
Similar presentations
Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.
Advertisements

Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008.
Peter Davies Senior Pharmacist.  Venous thromboembolic prevention is a DH patient safety priority  NICE clinical guideline venous thromboembolism reducing.
Educational Purposes. Coalition To Prevent VTE - Risk Assessment.
Thrombosis.TV Breaking Update: Betrixaban Approved by the FDA
Venous Thromboembolism Prophylaxis (VTE)
APEX Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for days (n = 3,759) versus subcutaneous.
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
NOACs for Cancer-Associated Thrombosis:
Acute Heart Failure.
Long-Term Treatment of VTE: Case Studies
Heart Failure and Hospital Readmissions
The Burden of Hospital-Associated Venous Thromboembolism
Thrombosis, Cancer, and NOACs
Does One Size Fit All in Obesity Management?
Access to NOAC Therapy:
NOACs in Clinical Practice: Are They All the Same?
New Strategies to Prevent CV Events After Hospital Discharge
A New Era for NOACs:.
Preventing VTE in hospitalised patients
The Safety and Efficacy of Full vs
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
Antithrombotics and PAD: A New Paradigm in Practice
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Heart Failure Prevention: Mission Impossible?
Blood pressure control: dependence on adherence
Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
Access to NOAC Therapy:
TAVR and the Risk of Thrombosis
Learning Objectives Classification of VTE Goals of VTE Treatment.
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
Risk Stratification in CAD and PAD
Real-World Evidence in VTE
Evaluating New Therapies in HF
Extending Treatment for Thrombosis: What’s the Right Choice?
Practical Considerations to Extend Treatment for VTE
Extraordinary Cases of VTE Prevention in Patients With Cancer
Anticoagulation and Thrombosis Management
Updates in Heart Failure:
APEX: Primary Efficacy and Safety Results
Long-Term Treatment of VTE: Case Studies
Factor Xa Inhibitors in PAD
CAD/PAD in Primary Care
A Time for Change for Managing Patients With VTE Who Have Cancer
Cancer-Associated Thrombosis
New Strategies to Reduce HF Readmissions
Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.
Managing Pulmonary Embolism Posthospital Discharge
Program Goals Background: Anticoagulation in Patients With VTE.
Factor Xa Inhibitors in Coronary Artery Disease
Improving Adherence to Antiplatelet Therapy After an ACS Event
An Unmet Need.
Disease Burden of VTE Phases of VTE Treatment.
5 Good Minutes on Atrial Fibrillation-related Stroke
Selecting Treatment Approaches in Hemophilia
Cardiff and Vale UHB Dr Graham Shortland
At the Crossroads of Coagulation
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Binge Eating Disorder.
My PAH Patient.
Key Data on Improving Outcomes in HF Patients
Navigating the Journey
Preventing Venous Thromboembolism Participating Hospital Survey
Presentation transcript:

Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care

Global Burden of VTE

Global Burden of VTE (cont)

Thrombosis UK

Virchow's Triad

Thrombosis in Medical Patients

Other Contributing Factors

Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care

Patients at Risk for VTE: Surgical Patients

Patients at Risk for VTE: Medical Patients

Patients at Risk for VTE: Other Factors

Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care

Patients at Risk for VTE

Multi-Disciplinary Approach

Electronic Alerts Reduce VTE

Thromboprophylaxis

Non-Pharmacologic Prophylaxis

Pharmacologic Prophylaxis

Summary

Summary (cont)

Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care

Trials of VTE Prophylaxis in Hospitalized Medical Patients

Previous Studies of Extended Thromboprophylaxis in Acute Medically Ill Patients

APEX Study Design

MAGELLAN D-Dimer

APEX Results

APEX Net Clinical Benefit (VTE or Major Bleed)

APEX Dose Reduction

Betrixaban FDA Approval

MARINER Trial Medical Patients at High Risk of VTE

MARINER vs APEX

Summary

Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care

VTE Risk After Discharge

VTE Risk Remains After Discharge

Improving Patient Outcomes

Abbreviations